Yu “Joshua” Cao (曹 宇), Ph.D.
EDUCATION & EXPERIENCE
|2017 – Present||Principal Investigator, Peking University, Shenzhen Graduate School|
|2016 – 2017||Senior Scientist, Sorrento Therapeutics Inc. (USA)|
|2013 – 2016||Research Associate, The Scripps Research Institute (Supervisor: Peter G. Schultz)|
|2007 – 2013||Postdoctoral Fellow, University of Texas, MD Anderson Cancer Center (Supervisor: Michael G. Rosenblum)|
|2001 – 2007||Ph.D., Nankai University (Advisor: Gang Bai)|
|1996 – 2000||B.Sc., Liaoning University|
During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments to improve the clinical efficacy. By critical thinking the distinct cell killing efficacy and potential unwanted toxicity of different targeted strategies, Dr. Cao’s lab is building versatile platforms and finding optimal strategies to develop novel immunotherapeutic agents for cancer treatment. Dr. Cao’s goal is to design the precision medicine approach for individual cancer patient groups for fully realizing the potential benefits of immunotherapy.